Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 469

Sort by

Sort Order Select

Journal Articles

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial

Blood blood.2025029210.

https://doi.org/10.1182/blood.2025029210

Published: 2025

Includes: Supplemental data

Journal Articles

Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with CML driven by atypical fusion transcripts

Andreas Hochhaus, Susanne Saussele, Valerie Coiteux, Dong-Wook Kim, Yingsi Yang, Qi Wang, Brianna Hoffner, Damiette Smit, Fabian Lang

Blood (2025) 146 (Supplement 1): 3771.

https://doi.org/10.1182/blood-2025-3771

Published: 2025

Journal Articles

Improved long-term tolerability and efficacy of asciminib-based combination therapies in newly diagnosed CML patients - the fascination trial.

Thomas Ernst, Philipp le Coutre, Martina Crysandt, Georg-Nikolaus Franke, Thomas Illmer, Andreas Burchert, Fabian Lang, Susanne Saussele, Lino Teichmann, Markus Radsak, Frank Stegelmann, Joachim Goethert, Stefan Krause, Jenny Rinke, Christian Fabisch, Thomas Lang, Markus Pfirrmann, Andreas Hochhaus

Blood (2025) 146 (Supplement 1): 903.

https://doi.org/10.1182/blood-2025-903

Published: 2025

Journal Articles

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML

Elias Jabbour, Timothy Hughes, Richard Van Etten, David Andorsky, Gonzalo Carreño, Philipp le Coutre, Omer Jamy, Pilar Giraldo, Dong-Wook Kim, Vivian Oehler, Andreas Hochhaus, Jorge Cortes, Michael Mauro, Tonya Marmon, Leanne Holes, Emil Kuriakose, Hagop Kantarjian, Delphine Rea

Blood (2025) 146 (Supplement 1): 901.

https://doi.org/10.1182/blood-2025-901

Published: 2025

Journal Articles

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

Blood (2025) 146 (Supplement 1): 75.

https://doi.org/10.1182/blood-2025-75

Published: 2025

Journal Articles

Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study

Blood (2025) 146 (Supplement 1): 73.

https://doi.org/10.1182/blood-2025-73

Published: 2025

Journal Articles

Vexas syndrome in Germany: Insights from a prospective registry on clinical presentation, management and outcomes

Blood (2025) 146 (Supplement 1): 4968.

https://doi.org/10.1182/blood-2025-4968

Published: 2025

Journal Articles

Evaluating reverse transcriptase efficiency in CML: Consequences for deep molecular response classification and treatment-free remission decisions

Katerina Machova Polakova, Hana Žižková, Pavla Suchankova, Katerina Rajnisova, Katerina Blagoevova, Romana Vajnerova, Helen White, Andreas Hochhaus, Nicholas Cross

Blood (2025) 146 (Supplement 1): 3762.

https://doi.org/10.1182/blood-2025-3762

Published: 2025

Journal Articles

MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”

Blood (2025) 146 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2025-1021

Published: 2025

Journal Articles

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Blood (2025) 146 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2025-1997

Published: 2025

Journal Articles

Nanopore sequencing to detect BCR::ABL1 and associated genomic rearrangements in CML

Matthew Salmon, Jenny Rinke, Thomas Ernst, William Tapper, Andreas Hochhaus, Helen White, Nicholas Cross

Blood (2025) 146 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2025-1995

Published: 2025

Journal Articles

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

Blood (2025) 146 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2025-1993

Published: 2025

Journal Articles

BCR::ABL1/GUSB halving times predict molecular response to asciminib at 18 months

Nicholas Cross, Thomas Ernst, Jenny Rinke, Hana Žižková, Alfred Cross, Katerina Machova Polakova, Birgit Spiess, William Tapper, Helen White, Andreas Hochhaus

Blood (2025) 146 (Supplement 1): 5553.

https://doi.org/10.1182/blood-2025-5553

Published: 2025

Journal Articles

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Blood (2025) 146 (Supplement 1): 5549.

https://doi.org/10.1182/blood-2025-5549

Published: 2025

Journal Articles

Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?

Blood (2025) 146 (Supplement 1): 5298.

https://doi.org/10.1182/blood-2025-5298

Published: 2025

Journal Articles

Ponatinib-based combination therapies including asciminib and venetoclax were effective on patient-derived xenograft models of chronic myeloid leukemia in blast Phase

Adam Laznicka, Nikola Curik, Jitka Krizkova, Katerina Rajnisova, Pavla Suchankova, Barbora Stefikova, Karyna Zhuk, Vaclava Polivkova, Eva Pokorna, Pavel Klener, Cyril Salek, Hana Klamova, Sarka Ransdorfova, Andreas Hochhaus, Katerina Machova Polakova

Blood (2025) 146 (Supplement 1): 3284.

https://doi.org/10.1182/blood-2025-3284

Published: 2025

Journal Articles

A phase II Study of fedratinib and nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment – fraction Study / IKF051 / gsg-MPN-006

Susanne Isfort, Nikolas Von Bubnoff, Haifa Kathrin Al-Ali, Heiko Becker, Frank Stegelmann, Thorsten Götze, Philipp le Coutre, Martin Griesshammer, Adrian Schwarzer, Luisa Wohn, Salah-Eddin Al-Batran, Johanna Riedel, Francesca Palandri, Kirsi Manz, Andreas Hochhaus, Konstanze Döhner, Florian Heidel

Blood (2025) 146 (Supplement 1): 5589.

https://doi.org/10.1182/blood-2025-5589

Published: 2025

Journal Articles

Cardinal: A Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tern-701 in Chronic Myeloid Leukemia

Elias Jabbour, Delphine Rea, Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Dong-Wook Kim, Hagop M. Kantarjian, Leanne Holes, Emil T. Kuriakose, Michael J. Mauro

Blood (2024) 144 (Supplement 1): 6594.

https://doi.org/10.1182/blood-2024-204153

Published: 2024

Journal Articles

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Blood (2024) 144 (Supplement 1): 3148.

https://doi.org/10.1182/blood-2024-207634

Published: 2024

Journal Articles

The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients

Thomas Ernst, Jenny Rinke, Philipp le Coutre, Martina Crysandt, Tim H. H. Brummendorf, Andreas Burchert, Fabian Lang, Susanne Saussele, Markus Pfirrmann, Thomas Lang, Christian Fabisch, Andreas Hochhaus

Blood (2024) 144 (Supplement 1): 1774.

https://doi.org/10.1182/blood-2024-193991

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial

Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with CML driven by atypical fusion transcripts

Improved long-term tolerability and efficacy of asciminib-based combination therapies in newly diagnosed CML patients - the fascination trial.

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

Vexas syndrome in Germany: Insights from a prospective registry on clinical presentation, management and outcomes

Evaluating reverse transcriptase efficiency in CML: Consequences for deep molecular response classification and treatment-free remission decisions

MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Nanopore sequencing to detect BCR::ABL1 and associated genomic rearrangements in CML

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

BCR::ABL1/GUSB halving times predict molecular response to asciminib at 18 months

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?

Ponatinib-based combination therapies including asciminib and venetoclax were effective on patient-derived xenograft models of chronic myeloid leukemia in blast Phase

A phase II Study of fedratinib and nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment – fraction Study / IKF051 / gsg-MPN-006

Cardinal: A Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tern-701 in Chronic Myeloid Leukemia

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only